Benzinga's M&A Chatter for Monday August 26, 2013
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday August 26, 2013:
Pritzker to Acquire TMS International for $17.50/Share in Cash
TMS International Corp. (NYSE: TMS) and The Pritzker Organization announced Monday that certain members of the Pritzker family will acquire TMS in an all-cash transaction valued at approximately $1 billion, including refinanced third-party debt. TMS stockholders will receive $17.50 in cash for each share of TMS Class A common stock and Class B common stock.
The deal is expected to close in Q4 2013.
TMS International closed at $17.48 Monday, a gain of 12%.
AstraZeneca's MedImmune Division to Acquire Amplimmune for Up to $500M(
AstraZeneca (NYSE: AZN) announced Monday that its MedImmune biologics research and development arm, will acquire Amplimmune, a privately-held, Maryland, US-based biologics company, for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching predetermined development milestones.
The deal is expected to close in Q3 2013.
AstraZeneca closed at $50.47 Monday, a loss of $0.20.
BATS, Direct Edge to Merge
BATS Global Markets and Direct Edge Holdings announced Monday a definitive merger agreement, which will create the second largest US exchange behind the NYSE (NYSE: NYX) and ahead of the Nasdaq (NASDAQ: NDAQ). Financial terms were not disclosed.
The deal is expected to close in H1 2014.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.